Stock Chart

GILD

$156.04 -0.73%
Score: 41.4 HOLD
LEAPs: SELL $175
i
LEAPs Option Signal

Type: SELL growth_1yr
Strike: $175
Premium: $12.70
Expiry: Sep 17, 2027
Target: $160
Score: -100

LEAPs are long-term options (1+ year) with less time decay.
Pro
Screener
Vol: 1.09x (vs SPY: 1.3x | vs QQQ: 1.3x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 23, 2026
Rising Channel weak / forming — below our quality gate quality 52/100
A Rising Channel is taking shape but hasn't passed our quality gate (60/100), so no projected path or levels are shown — only the forming rails on the chart below.
Lower rail breaks first 80% of the time (n=1,744) — a trend-exit tell, not a crash call
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About GILD - Gilead Sciences Inc

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Key Statistics

Market Cap $195B
Dividend Yield 0.02%

This GILD stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track GILD's price movements with trendlines, gamma walls, and key support/resistance levels.